| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 04/07/2005 | US20050075349 Xanthine phosphodiesterase V inhibitors |
| 04/07/2005 | US20050075334 Novel compounds |
| 04/07/2005 | US20050075313 Ophthalmic compositions containing galactomannan polymers and borate |
| 04/07/2005 | US20050074470 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 04/07/2005 | US20050074455 Treatment of neovascular opthalmic disease |
| 04/07/2005 | US20050074436 Systems and methods for treating patients with processed lipoaspirate cells |
| 04/07/2005 | US20050072430 Nasal devices |
| 04/07/2005 | CA2539472A1 Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid |
| 04/07/2005 | CA2537874A1 Therapeutic agent for ageing macular degeneration |
| 04/06/2005 | EP1519962A1 Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring |
| 04/06/2005 | EP1519961A1 Low molecular weight oversulfated polysaccharide |
| 04/06/2005 | EP1519920A1 Novel tetrahydropyridine derivatives as renin inhibitors |
| 04/06/2005 | EP1519754A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 04/06/2005 | EP1519746A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 04/06/2005 | EP1519732A1 Use of vasopeptidase inhibitors in the treatment of nephropathy |
| 04/06/2005 | EP1519731A1 Combination of azelastine and steroids |
| 04/06/2005 | EP1519730A1 Novel use of imidazotriazinones |
| 04/06/2005 | EP1519726A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 04/06/2005 | EP1519722A1 Glycoloyl-substituted oxazolidinone-derivatives as antibacterial agents |
| 04/06/2005 | EP1480627A4 Methods of reducing angiogenesis |
| 04/06/2005 | EP1334086B1 Phenoxyphenyl alkane sulfonates |
| 04/06/2005 | EP1307455B1 Inhibitors of alpha-l beta-2 mediated cell adhesion |
| 04/06/2005 | EP1227809B1 Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use |
| 04/06/2005 | EP1113809B1 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor |
| 04/06/2005 | EP1090012A4 Inhibitors of prenyl-protein transferase |
| 04/06/2005 | EP1090011A4 Inhibitors of prenyl-protein transferase |
| 04/06/2005 | EP0748219B1 Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| 04/06/2005 | CN1604968A Methods to treat diabetes and related conditions based on polymorphisms in the TCF-1 gene |
| 04/06/2005 | CN1604965A 生长激素融合蛋白 Growth hormone fusion protein |
| 04/06/2005 | CN1604904A Phosphonic acid compounds as inhibitors of serine proteases |
| 04/06/2005 | CN1604794A Eye drops |
| 04/06/2005 | CN1604784A Heparin-containing ophthalmic agent |
| 04/06/2005 | CN1604775A Modulation of ocular growth and myopia by GABA drugs |
| 04/06/2005 | CN1604774A 血管生成抑制剂 An angiogenesis inhibitor |
| 04/06/2005 | CN1604773A Treatment of faecal incontinence and other conditions with 1r, 2s-methoxamine |
| 04/06/2005 | CN1604770A Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs |
| 04/06/2005 | CN1603342A Caspase-8 interacting proteins |
| 04/06/2005 | CN1602847A Bupicomide hydrochloride drop pills and its preparation method |
| 04/06/2005 | CN1195773C Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 04/06/2005 | CN1195735C Sulfonylamino derivatives which inhibit matrix-degrading metallopr teinases |
| 04/06/2005 | CN1195547C Preventives / remedies for glaucoma |
| 04/06/2005 | CN1195522C Benzodiazepine derivatives |
| 04/05/2005 | US6875789 Pyrazole-derived kinase inhibitors and uses thereof |
| 04/05/2005 | US6875779 Cyclooxygenase inhibitor |
| 04/05/2005 | US6875767 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors |
| 04/05/2005 | US6875570 Proteins and nucleic acids encoding same |
| 04/05/2005 | CA2371012C 4-(1h-pyrrol-1-yl) imidazoles |
| 03/31/2005 | WO2005028476A1 Substituted indolizine 1,2,3,6,7,8 derivatives, fgfs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives |
| 03/31/2005 | WO2005027973A2 Combinations of a vegf receptor inhibitor with other therapeutic agents |
| 03/31/2005 | WO2005027969A1 Remedy for eye diseases accompanied by optic nerve injuries |
| 03/31/2005 | WO2005027893A1 HUMAN β-DEFENSIN SECRETION PROMOTER |
| 03/31/2005 | WO2005002520A3 Ophthalmic compositions for treating ocular hypertension |
| 03/31/2005 | WO2004108133A3 Modulators of vr1 receptor |
| 03/31/2005 | WO2004010951A8 Method of treating tumors |
| 03/31/2005 | WO2003073987A3 Compounds that modulate the activity of ptp-1b and tc-ptp |
| 03/31/2005 | WO2003018756A3 Methods for preparing purified prostaglandin e synthase |
| 03/31/2005 | WO2002042319A9 2-substituted estrogens as antiangiogenic agents |
| 03/31/2005 | US20050070720 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 03/31/2005 | US20050070691 Polypeptides of moraxella (branhamella) catarrhalis |
| 03/31/2005 | US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders |
| 03/31/2005 | US20050070606 Pharmaceutical agent for mitochondrial disorders |
| 03/31/2005 | US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity |
| 03/31/2005 | US20050070582 For example,1-{[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl}-4-ethylpiperazine or 1-{[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl}piperazine; for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders |
| 03/31/2005 | US20050070574 Novel compounds |
| 03/31/2005 | US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors |
| 03/31/2005 | US20050070566 Imidazoquinoline derivatives |
| 03/31/2005 | US20050070555 Aroyl pyridinones |
| 03/31/2005 | US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 03/31/2005 | US20050070468 Use of fk506 and analogues for treating allergic diseases |
| 03/31/2005 | US20050070466 Diagnostic imaging agents; targeting vectors which bind to integrin receptors; bicyclic arginine-glycine-aspartic acid derivatives; stablility; reduced background interference |
| 03/31/2005 | US20050069893 Diagnostic method for glaucoma |
| 03/31/2005 | US20050069878 Proteins associated with cell growth, differentiation, and death |
| 03/31/2005 | US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders. |
| 03/31/2005 | US20050069598 Antidiabetic agents; moderate glucagon-like peptide; phosphoenolpyruvate carboxykinase inhbitors; weight control |
| 03/31/2005 | US20050069492 As neuroprotective agents in the therapy of neuronal disorders of the central and peripheral nervous systems |
| 03/31/2005 | CA2539230A1 Combinations of a vegf receptor inhibitor with other therapeutic agents |
| 03/31/2005 | CA2538760A1 Human .beta.-defensin secretion promoter |
| 03/30/2005 | EP1517924A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained |
| 03/30/2005 | EP1517909A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| 03/30/2005 | EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors |
| 03/30/2005 | EP1517686A2 Use of dantrolene, a ryanodine antagonist, in treating neural injury |
| 03/30/2005 | EP1390025B1 Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders |
| 03/30/2005 | EP1360184B1 Piperidine derivatives as neurokinin 1 antagonists |
| 03/30/2005 | EP1250133B1 Ophthalmic anti-allergy compositions suitable for use with contact lenses |
| 03/30/2005 | EP1242089B1 Use of adatanserin for the treatment of acute neurodegenerative disorders |
| 03/30/2005 | EP1124570A4 Novel neuropilin/growth factor binding and uses thereof |
| 03/30/2005 | EP0980369B1 Sulfonamides for treatment of endothelin-mediated disorders |
| 03/30/2005 | EP0804194B1 Use of retinoic acid receptor-agonists or ap-1 antagonists for the manufacture of a medicament for preventing proliferation of retinal pigment epithelium |
| 03/30/2005 | CN1602317A Angiopoietin-2 specific binding agents |
| 03/30/2005 | CN1602292A Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists |
| 03/30/2005 | CN1602207A Methods for inhibiting ocular processes |
| 03/30/2005 | CN1602199A Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| 03/30/2005 | CN1602198A Pharmaceutical composition for use in ophthalmology and rhinology |
| 03/30/2005 | CN1602191A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 03/30/2005 | CN1602187A Valdecoxib-based composition prepared by spray drying process and exhibiting rapid oral dissolution |
| 03/30/2005 | CN1194976C Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| 03/30/2005 | CN1194686C Eye drops of fluconazole |
| 03/30/2005 | CN1194685C Ophthalmic gel of marticarpine |
| 03/30/2005 | CN1194677C Long-acting tretnoin intraocular slowly-releasing system |
| 03/30/2005 | CN1194664C In-vivo gel preparation able to be dropped in eyes and its preparing process |